Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina

Medical Clinic II, University of Mainz, Germany.

OBJECTIVES. This study was performed to evaluate the efficacy of peri-interventional treatment with recombinant hirudin (r-hirudin [HBW 023]) compared with heparin in the prevention of troponin T release in patients with unstable angina. BACKGROUND. Percutaneous transluminal coronary angioplasty in patients with unstable angina is associated with a high risk of acute thrombotic complications. METHODS. Serial troponin T measurements were performed in 61 patients with unstable angina during the 48-h observation period after coronary angioplasty of the ischemia-related lesion. Patients were randomly assigned to peri-interventional intravenous treatment with either r-hirudin (dosage group I: 0.3-mg/kg body weight bolus, 0.12 mg/kg per h for 24 h; dosage group II: 0.5-mg/kg bolus, 0.24 mg/kg per h for 24 h) or heparin (150-IU/kg bolus, 20 IU/kg per h for 24 h). All patients received acetylsalicylic acid before coronary angiography. After 24 h, patients received a constant low dose infusion of either hirudin (0.04 mg/kg per h) or heparin (7 IU/kg per h) for another 24 h. The power of the study to detect a decrease in abnormal troponin T levels from 60% (heparin group) to 20% (combined r-hirudin groups) was 88%. RESULTS. Serial troponin T measurements revealed two peaks within the 48 h after coronary angioplasty in the heparin but not the hirudin groups. An elevated serum troponin T concentration (> 0.2 ng/ml) within 48 h of coronary angioplasty was found in 9 (24%) of 38 patients in the hirudin groups (5 [25%] of 20 in dosage group I; 4 [22%] of 18 in dosage group II) compared with 11 (58%) of 19 in the heparin group (p = 0.01). We observed major cardiac events (death, myocardial infarction, abrupt vessel closure) in 1 (4.8%) of 21 patients in dosage group I, 1 (5.3%) of 19 in dosage group II and 3 (14.3%) of 21 in the heparin group (p = 0.33). CONCLUSIONS. In this pilot trial, hirudin appears to be superior to heparin in preventing troponin T release after coronary angioplasty.

This article has been cited by other articles:

				Y. J. Hong, G. S. Mintz, S. W. Kim, S. Y. Lee, T. Okabe, A. D. Pichard, L. F. Satler, R. Waksman, K. M. Kent, W. O. Suddath, et al. Impact of Plaque Composition on Cardiac Troponin Elevation After Percutaneous Coronary Intervention: An Ultrasound Analysis J. Am. Coll. Cardiol. Img., April 1, 2009; 2(4): 458 - 468. [Abstract] [Full Text] [PDF]

				T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]

				T. E. Warkentin and A. Greinacher Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 311S - 337S. [Abstract] [Full Text] [PDF]

				W. J. Cantor, L. K. Newby, R. H. Christenson, R. H. Tuttle, V. Hasselblad, P. W. Armstrong, D. J. Moliterno, R. M. Califf, E. J. Topol, E. M. Ohman, et al. Prognostic significance of elevated troponin i after percutaneous coronary intervention J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1738 - 1744. [Abstract] [Full Text] [PDF]

				A. Greinacher and N. Lubenow Recombinant Hirudin in Clinical Practice : Focus on Lepirudin Circulation, March 13, 2001; 103(10): 1479 - 1484. [Abstract] [Full Text] [PDF]

				A. Greinacher, H. Volpel, U. Janssens, V. Hach-Wunderle, B. Kemkes-Matthes, P. Eichler, H. G. Mueller-Velten, and B. Potzsch Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia : A Prospective Study Circulation, January 12, 1999; 99(1): 73 - 80. [Abstract] [Full Text] [PDF]

				E. M. Ohman and B. E. Tardiff Periprocedural Cardiac Marker Elevation After Percutaneous Coronary Artery Revascularization: Importance and Implications JAMA, February 12, 1997; 277(6): 495 - 497. [Abstract] [PDF]

				A. E. Abdelmeguid and E. J. Topol The Myth of the Myocardial `Infarctlet' During Percutaneous Coronary Revascularization Procedures Circulation, December 15, 1996; 94(12): 3369 - 3375. [Full Text]